According to Prothena's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.34783. At the end of 2022 the company had a P/E ratio of -24.1.
Year | P/E ratio | Change |
---|---|---|
2022 | -24.1 | -167.81% |
2021 | 35.5 | -925.61% |
2020 | -4.30 | -46.97% |
2019 | -8.12 | 210.53% |
2018 | -2.61 | -71.69% |
2017 | -9.23 | -12.52% |
2016 | -10.6 | -59.24% |
2015 | -25.9 | -90.02% |
2014 | -260 | 2072.29% |
2013 | -11.9 | 302.73% |
2012 | -2.97 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | 20.6 | -715.44% | ๐ฎ๐ช Ireland |
![]() | -56.5 | 1,586.82% | ๐บ๐ธ USA |
![]() | -74.3 | 2,119.40% | ๐ฎ๐ช Ireland |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.